Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

SMS Pharmaceuticals Limited

NSE: SMSPHARMAPharmaceuticals

Share price

₹444.65

-0.47% close of 9 Oct 2026

Market cap ₹4,184 CrP/E 39.3 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

59

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹4,184 Cr

P/E ratio

39.3

P/B ratio

5.3

ROCE

13.3%

ROE

14.3%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹483.3552-week low ₹271.55

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.2% over the past year, and 11.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 10.2% to 19.3% over the last four years.

Whether it grew faster than its sector

It grew 11.4% a year against a sector median of 13.1% — 1.7 percentage points slower.

Room to re-rate, or risk of de-rating

At 39.3× earnings it costs 1.6× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 30.9×, the 84th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.3 times its growth rate, on earnings growth of 155%.

Profit growthPrice per ₹1 profitPer 1% growth
SMS Pharmaceuticals Limited — this one155%/yr39.3×—
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7
Cipla10%/yr29.6×₹3.0

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 72 of 130 on returns, 65 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 13.3% on capital, ahead of 45% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹258 crore of cash from the business but spent ₹361 crore on plant and equipment, ₹103 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹263 crore to ₹365 crore. And the profit is real: of every 100 rupees it reported over 12 years, about 115 arrived as cash (before interest, which is why it can exceed the profit).

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit rose 5% on the year to Rs 21 Cr, and was down 37% from the March quarter.

Announced 31 Jul 2026 · Consolidated

Revenue

₹207 Cr

Revenue vs last year

+5.6%

Revenue vs last quarter

-13.0%

Net profit

₹21 Cr

Profit vs last year

+4.5%

Profit vs last quarter

-36.6%

Net margin

10.1%

EPS

₹2.23

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹4,184 Cr
Prev close
₹444.65
52w High
₹494
52w Low
₹264
Enterprise value
₹4,340 Cr
Beta
1.3
Price CAGR 1y
78.0%
Price CAGR 3y
57.0%
Price CAGR 5y
25.0%
Price CAGR 10y
18.0%

Ratios

Return on assets
7.5%
PEG ratio
0.3
P/E ratio
39.3
P/B ratio
5.3
EV / EBITDA
25.1
Industry P/E
38.0
ROCE
13.3%
ROCE 5y average
11.0%
ROE
14.3%
Debt / Equity
0.5
Interest coverage
6.1
Dividend yield
0.1%
ROE 3y average
12.0%
ROE last year
14.0%

Annual P&L

Annual revenue
₹887 Cr
Annual profit
₹102 Cr
Operating margin
19.0%
Net profit margin
11.5%
EBITDA margin
19.3%
Sales growth 3y
19.3%
Sales growth 5y
9.5%
Profit growth 3y
155.0%
Profit growth 5y
10.0%
EPS
₹10.9
Sales growth TTM
10.0%
Profit growth TTM
40.0%
Dividend payout
4.0%

Quarter P&L

Sales latest quarter
₹207 Cr
Profit latest quarter
₹21 Cr
YoY quarterly sales growth
5.6%
YoY quarterly profit growth
5.0%
OPM latest quarter
19.8%

Balance Sheet

Book Value
₹87.2
Face Value
₹1.0
Total debt
₹365 Cr
Total cash
₹46 Cr
Borrowings
₹365 Cr
Reserves / Equity
86.2

Cash Flow

Operating cash flow
₹59 Cr
Free cash flow
-₹71 Cr
FCF yield
-2.2%
Net cash flow
₹4 Cr

Shareholding

Promoter holding
68.1%
FII holding
0.7%
DII holding
2.8%
Public holding
28.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,751.0033.24,20,1240.902,901.26.015,299.910.520.5
Divi's Lab.9,431.0084.02,50,3630.31902.065.53,080.027.822.0
Torrent Pharma.4,631.0579.01,76,1500.81566.05.84,921.054.915.2
Zydus Lifesci.1,114.7522.91,11,1970.09990.2-35.18,017.022.021.1
Laurus Labs2,023.15100.01,09,3130.10362.1125.52,026.329.117.8
Cipla1,298.2029.31,04,8780.98785.6-39.27,119.32.315.5
Mankind Pharma2,381.8046.198,3790.04574.129.64,030.612.913.5
SMS Pharma.451.0041.24,2240.0920.92.0207.05.613.3
Median410.0034.32,1130.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales135167161246164197173248196242210238207
Expenses109139132212131165140207157194167198166
Material Cost118147107139128137
Change in Inventories30-3633-254.76-24
Purchases of Stock-in-Trade000000
Employee Cost271819212924
Other Expenses332835323530
Operating Profit26282934343133413948444041
OPM %19171814201619162020211720
Other Income1112112111432
Exceptional items (within Other Income)000000
Interest6666554566656
Depreciation888889991010101010
Profit before tax13151722222022292434312727
Tax %31212626252924302326262326
Net Profit9121117161418202025233321
EPS in Rs1.101.381.362.041.951.662.152.292.312.702.513.492.23
Diluted EPS in Rs2.402.312.842.593.582.23

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales193611438463465412563520522709783887898
Expenses145522363369375332442405467593644716725
Material Cost502516
Change in Inventories-65-23
Purchases of Stock-in-Trade00
Employee Cost8088
Other Expenses127134
Operating Profit47897593908012111555117139171173
OPM %25151720191922221016181919
Other Income5412353554689
Exceptional items (within Other Income)00
Interest8171615121211192224192323
Depreciation5191920192222323232344040
Profit before tax405642606251916856692117119
Tax %36261433343633128262725
Net Profit2541283240326362-75069102102
EPS in Rs2.554.833.363.754.733.737.387.35-0.835.887.801111
Diluted EPS in Rs8.1611
Dividend Payout %84675744-36754

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
4%
5 years
10%
3 years
19%
TTM
10%

Compounded profit growth

10 years
10%
5 years
10%
3 years
155%
TTM
40%

Stock price CAGR

10 years
18%
5 years
25%
3 years
57%
1 year
78%

Return on equity

10 years
11%
5 years
10%
3 years
12%
Last year
14%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital10888888888.478.879
Reserves182285246276313340402462452528631776
Borrowings73204149146144157255263254281311365
Other Liabilities64158897293103147126165217202212
Minority Interest0.000.00
Total Liabilities3296564935035596088128608801,0341,1531,362
Fixed Assets69370290279281280457438412437533534
CWIP1513881842711333035122
Investments02129282726272211111226
Other Assets245252166187232259321389424556573681
Total Assets3296564935035596088128608801,0341,1531,362

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity146173325040904522508259
Cash from Investing Activity-32-97-39-17-35-43-152-27-30-52-123-131
Cash from Financing Activity10727-33-15-13-292-12-32314776
Net Cash Flow89-9102-5316-392954
Free Cash Flow-5-27502315-3-6118-7-2-41-71

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days114361819204368341041229589
Inventory Days165106114135170191148333243201238260
Days Payable72798249596670971171309589
Cash Conversion Cycle2066350105131169146270230192237260
Working Capital Days16919-22739574894104858898
ROCE %1318171317134121313

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters646465656565666668686868
FIIs0.600.590.170.180.520.310.080.030.280.040.310.65
DIIs001.982.132.552.552.433.032.883.213.022.83
Public353533333232313129292928
No. of Shareholders25,24625,34130,14031,78033,13634,97335,33233,65234,15734,37832,39731,489

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +63.7% (₹271.67 → ₹444.65)Brick size ₹21.32 (fixed)Bricks 17
₹300₹400₹445Nov '25May '26
Price moved up one brickPrice moved down one brickLast close ₹444.65 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

319inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

54,84,669inr

2026-03-31

News

News and filings about SMS Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Key starting materials & API intermediates
  • Organic solvents
  • Packing materials

Depends on the price of

  • fuel

Buys drug ingredients from

  • SMS Lifesciences India Limited

Sells to

  • Global generic-drug formulators (800+ customers across 75+ countries) · APIs & complex intermediates (anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-dia…

Buys from

  • HALEOS LABS LIMITED · APIs and intermediates; FY25 RPT sale of goods Rs 1,924.05 lakh (purchases from them only…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE812G01025

Plants

  • SMS Pharma Bachupally API facility
  • SMS Pharma R&D Centre
  • SMS Pharma Vizag Ibuprofen API facility
  • SMS Pharma Vizianagaram API facility

News impact

Big market events that reach SMS Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

22 Sep 2026unspecified₹0.4
22 Sep 2025unspecified₹0.4
23 Sep 2024unspecified₹0.4
22 Sep 2023unspecified₹0.3
22 Sep 2022unspecified₹0.3
22 Sep 2021unspecified₹0.3
26 Mar 2020interim₹0.25
19 Sep 2019unspecified₹0.25

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
11 Sep 2026MICROCURVES TRADING PRIVATE LIMITEDBUY5,46,684₹454.34
11 Sep 2026MICROCURVES TRADING PRIVATE LIMITEDSELL5,46,684₹454.45

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
21 Sep 2026NVV Satyanarayana · Designated PersonSELL2,0500.10
21 Sep 2026NVV Satyanarayana · Designated PersonSELL1,0000.05
24 Aug 2026N. Srilakshmi Padmini · Employees Immediate RelativeBUY3,0000.11

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.